These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23536317)

  • 1. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
    Maguire DR; Yang W; France CP
    J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
    Gerak LR; France CP
    J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
    Li JX; McMahon LR; Gerak LR; Becker GL; France CP
    Psychopharmacology (Berl); 2008 Aug; 199(2):199-208. PubMed ID: 18470505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists.
    Maguire DR; France CP
    J Pharmacol Exp Ther; 2014 Nov; 351(2):383-9. PubMed ID: 25194020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
    Maguire DR; France CP
    Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids.
    Erwin LL; Nilges MR; Denys IB; Sutphen JC; Friend AJ; Kapusta DR; Winsauer PJ
    Pharmacol Biochem Behav; 2021 Aug; 207():173218. PubMed ID: 34118232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.
    Gerak LR; Zanettini C; Koek W; France CP
    Psychopharmacology (Berl); 2015 Oct; 232(19):3637-47. PubMed ID: 26202613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
    Hruba L; McMahon LR
    Eur J Pharmacol; 2014 Mar; 727():35-42. PubMed ID: 24486701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
    J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.
    Maguire DR; France CP
    Psychopharmacology (Berl); 2018 Aug; 235(8):2357-2365. PubMed ID: 29860612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
    Maguire DR; France CP
    Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.
    Weed PF; Gerak LR; France CP
    Eur J Pharmacol; 2018 Aug; 833():94-99. PubMed ID: 29807027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
    Minervini V; Dahal S; France CP
    J Pharmacol Exp Ther; 2017 Feb; 360(2):280-287. PubMed ID: 27903642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
    da Fonseca Pacheco D; Klein A; de Castro Perez A; da Fonseca Pacheco CM; de Francischi JN; Duarte ID
    Br J Pharmacol; 2008 Jul; 154(5):1143-9. PubMed ID: 18469844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
    Smith PA; Selley DE; Sim-Selley LJ; Welch SP
    Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.